On July 9, 2024, an Ohio State senior received what she calls her “miracle match.” Ella DuBro, a fourth-year in human development and family sciences, recently celebrated the one-year anniversary of her double lung transplant at The Ohio State University Wexner Medical Center Comprehensive Transplant Center. DuBro’s transplant surgery was the culmination of a multi-year […]
Thai phụ 11 tuần nhập viện Bệnh Nhiệt đới Trung ương trong tình trạng nguy kịch do suy hô hấp tiến triển nhanh. Cần cẩn trọng với các bệnh lý hô hấp khi mang thai!
#suyhôhấp #thainghén #bệnhviệnnhiệtđới
#hô hấp #mangthai #sứckhỏe
#respiratoryfailure #pregnancy #health
High-flow nasal oxygen (HFNO) is a type of non-invasive advanced respiratory support that allows the delivery of high-flow and humidified air through a nasal cannula. It can deliver a higher inspired oxygen fraction than conventional oxygen therapy (COT), improves secretion clearance, has a small positive end-expiratory pressure, and exhibits a washout effect on the upper air space that diminishes dead space ventilation. HFNO has been shown to reduce the work of breathing in acute hypoxemic respiratory failure (AHRF) and has become an interesting option for non-invasive respiratory support. Evidence published before the COVID-19 pandemic suggested a possible reduction of the need for invasive mechanical ventilation compared to COT. The COVID-19 pandemic has resulted in a substantial increase in AHRF worldwide, overwhelming both acute and intensive care unit capacity in most countries. This triggered new trials, adding to the body of evidence on HFNO in AHRF and its possible benefits compared to COT or non-invasive ventilation. We have summarized and discussed this recent evidence to inform the best supportive strategy in AHRF both related and unrelated to COVID-19.
Columbus - Feeds
VTC News Bot
Ars Technica News
Thomas Agoritsas, MD, PhD